Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany.
J Thorac Cardiovasc Surg. 2012 Dec;144(6):1510-6. doi: 10.1016/j.jtcvs.2012.07.095. Epub 2012 Aug 31.
Patients requiring extracorporeal cardiorespiratory support during lung transplantation can be treated with conventional cardiopulmonary bypass (CPB) or venoarterial extracorporeal membrane oxygenation (ECMO). In a retrospective analysis, we compared the postoperative course and outcomes of patients treated using these approaches.
Between August 2008 and September 2011, 92 consecutive patients underwent lung transplantation with extracorporeal support (CPB group, n = 46; and, since February 2010, ECMO group, n = 46) at our institution. We evaluated survival, secondary organ failure, bleeding complications, and the need for blood and platelet transfusions in these 2 patient populations.
Intraoperatively, the CPB group required more packed red blood cell transfusions (12 ± 11 vs 7 ± 9 U; P = .01) and platelet concentrates (2.5 ± 1.6 vs 1.5 ± 1 U; P < .01) than the ECMO group. In-hospital mortality (39% vs 13%; P = .004), the need for hemodialysis (48% vs 13%; P < .01), and new postoperative ECMO support (26% vs 4%; P < .01) were greater in the CPB group than in the ECMO group, respectively. After propensity score analysis, multivariate analysis identified retransplantation (odds ratio, 7; 95% confidence interval, 1-43; P = .034) and transplantation with CPB support (odds ratio, 4.9; 95% confidence interval, 1.2-20; P = .026) as independent risk factors for in-hospital mortality. The survival rate at 3, 9, and 12 months was 70%, 59%, and 56% in the CPB group and 87%, 81%, and 81% in the ECMO group (P = .004).
Intraoperative ECMO allows for better periprocedural management and reduced postoperative complications and confers a survival benefit compared with CPB, mainly because of lower in-hospital mortality. It is now the standard of care in our lung transplantation program.
在肺移植过程中需要体外心肺支持的患者可以使用传统心肺转流(CPB)或静脉动脉体外膜氧合(ECMO)进行治疗。在回顾性分析中,我们比较了使用这些方法治疗的患者的术后过程和结局。
2008 年 8 月至 2011 年 9 月,我们机构连续 92 例患者接受了体外支持下的肺移植(CPB 组,n=46;自 2010 年 2 月起,ECMO 组,n=46)。我们评估了这两组患者的存活率、继发性器官衰竭、出血并发症以及对血液和血小板输注的需求。
术中,CPB 组需要输注更多的浓缩红细胞(12±11 比 7±9 U;P=0.01)和血小板浓缩物(2.5±1.6 比 1.5±1 U;P<0.01)。CPB 组患者院内死亡率(39%比 13%;P=0.004)、需要血液透析(48%比 13%;P<0.01)和新术后 ECMO 支持(26%比 4%;P<0.01)均高于 ECMO 组。在进行倾向评分分析后,多变量分析确定了再次移植(优势比,7;95%置信区间,1-43;P=0.034)和 CPB 支持下的移植(优势比,4.9;95%置信区间,1.2-20;P=0.026)是院内死亡率的独立危险因素。CPB 组患者的 3、9 和 12 个月生存率分别为 70%、59%和 56%,ECMO 组患者分别为 87%、81%和 81%(P=0.004)。
与 CPB 相比,术中 ECMO 可更好地进行围手术期管理,减少术后并发症,并带来生存获益,主要是因为院内死亡率较低。它现在是我们肺移植项目中的标准治疗方法。